{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE299nnn/GSE299507/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Mus musculus"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299507"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Combination with oxaliplatin improves abscopal effect of oncolytic virotherapy through reorganization of intratumoral macrophages II","description":"Oncolytic virotherapy is a unique and promising immunotherapy. In our prior study, a recombinant oncolytic vaccinia virus carrying IL-7 and IL-12 (hIL-7/mIL-12-VV) showed robust antitumor efficacy in both immunogenic CT26.WT and poorly immunogenic Lewis lung carcinoma (LLC) within the treated tumors. However, the efficacy was limited in virus non-treated (distant) LLC tumors. Here we identified oxaliplatin as a powerful combination partner for an oncolytic vaccinia virus to achieve strong efficacy in the virus-injected tumors and the distant tumors. To understand the molecular mechanism of abscopal effect of hIL-7/mIL-12-VV in combination with oxaliplatin, we evaluated RNA-sequencing signatures of LLC tumors on the virus non-treated side.","dates":{"publication":"2026/07/01"},"accession":"GSE299507","cross_references":{"GSM":["GSM9039989","GSM9039987","GSM9039988","GSM9039985","GSM9039986","GSM9039983","GSM9039984","GSM9039982","GSM9040003","GSM9040002","GSM9040001","GSM9040000","GSM9040009","GSM9040008","GSM9039998","GSM9040007","GSM9039999","GSM9040006","GSM9040005","GSM9039996","GSM9039997","GSM9040004","GSM9039994","GSM9039995","GSM9039992","GSM9039993","GSM9039990","GSM9039991","GSM9040011","GSM9040010"],"GPL":["24247"],"GSE":["299507"],"taxon":["Mus musculus"]}}